INOVIO Doses First Subject in Phase 2 Segment of its INNOVATE ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
PLYMOUTH MEETING, Pa., Dec. 7, 2020 /PRNewswire-AsiaNet/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced it has dosed its first subject in a Phase 2 clinical tria...
Authors: LATEST ASIANET NEWS RELEASES